Treatment or prevention of tolerance to nitro compound vasodilators, comprises administration of melatonin or melatoninergic ligands, especially useful in chronic treatment of cardiac disorders such as angina

摘要

Use of melatonin (MT) or melatoninergic ligands (MTL) comprises compositions for the treatment and/or prophylaxis in the development of tolerance to nitro compounds (NC). Independent claims are included for compositions comprising MT or MTL (agonists or antagonists) and optionally NC, together with excipients.